Loading organizations...
§ Private Profile · San Francisco, CA, USA
Nalu Bio is a technology company.
Nalu Bio develops next-generation therapeutics by targeting the endocannabinoid system (ECS) to address inflammatory, immune, and metabolic diseases. The company employs an AI-driven and biological modeling platform to accelerate the discovery and development of novel, safe, and efficacious ECS-based solutions. This approach allows Nalu Bio to create precision therapeutics designed to restore balance in the body, moving beyond traditional plant-derived compounds to pharmaceutical-grade ingredients.
The company was founded in 2019 by Caitlyn Krebs, Phyllis Whiteley, and Randall Ussery. The founders recognized the significant yet largely overlooked potential of the endocannabinoid system in regulating key bodily functions like pain, inflammation, and metabolism. Their insight centered on bringing scientific rigor to this system, leveraging their collective expertise to overcome historical stigmas and unlock new therapeutic avenues for various health challenges.
Nalu Bio's focus is on providing solutions for individuals suffering from chronic inflammatory, immune, and metabolic conditions. The company’s vision is to mainstream ECS-based therapeutics, filling a critical gap in pharmaceutical pipelines with targeted treatments. By developing non-addictive and effective solutions, Nalu Bio aims to harness the body's own regulatory mechanisms to improve human health and address the root causes of modern diseases.
Nalu Bio has raised $14.0M across 2 funding rounds.
Nalu Bio has raised $14.0M in total across 2 funding rounds.
Nalu Bio is a biotechnology company pioneering a first-of-its-kind drug discovery platform targeting the endocannabinoid system (ECS), a critical but underexplored biological network that regulates pain, inflammation, mood, metabolism, immune response, and hormone cycles. The company leverages AI and biological modeling to accelerate the development of novel, safe, non-addictive, and effective ECS-based therapeutics and wellness products. Nalu Bio serves both prescription and nonprescription markets, offering vitamins, minerals, supplements, and therapeutic candidates aimed at addressing widespread health challenges such as pain, anxiety, sleep disorders, weight management, and mobility issues. Their products are designed for global consumer packaged goods (CPG) and therapeutics companies, emphasizing precision, safety, scalability, and sustainability[1][2][4].
Founded in 2019 in San Francisco, Nalu Bio was established by a female-led team with deep expertise in chemistry, AI, and health innovation. The idea emerged from recognizing the ECS as a powerful but largely untapped system with the potential to address modern health burdens linked to inflammation, immune dysfunction, and metabolic diseases. Early traction came from developing proprietary AI-powered platforms trained on tens of thousands of compounds to identify effective cannabinoid and bioactive combinations. This approach enables faster, lower-cost drug discovery and product development, positioning Nalu Bio at the forefront of ECS therapeutics and wellness innovation[1][2][3].
Nalu Bio rides the convergence of biotechnology, AI, and cannabinoid science, capitalizing on growing regulatory acceptance (e.g., FDA botanical drug pathways) and increasing demand for safe, effective alternatives to traditional pharmaceuticals. The timing is critical as the global rise in inflammatory, immune, and metabolic diseases creates urgent need for novel therapies. By unlocking the ECS’s therapeutic potential through AI-driven chemistry, Nalu Bio is positioned to influence both the pharmaceutical and wellness sectors, driving a shift comparable to the introduction of vitamins decades ago. Their approach also addresses sustainability and scalability challenges inherent in plant-based cannabinoid production, aligning with broader market and environmental trends[1][2][4].
Looking ahead, Nalu Bio is poised to expand its impact by advancing its ECS drug discovery pipeline and scaling partnerships with global CPG and therapeutics companies. Trends such as personalized medicine, AI-enabled drug development, and increasing consumer demand for natural yet scientifically validated health solutions will shape their trajectory. As regulatory frameworks evolve and ECS science matures, Nalu Bio’s influence could grow substantially, potentially transforming how cannabinoids are integrated into mainstream medicine and wellness. Their continued innovation in chemistry-derived cannabinoids and AI-driven discovery positions them to lead the next wave of ECS-based health solutions, fulfilling their mission to solve modern health challenges at scale[1][4][6].
Nalu Bio has raised $14.0M in total across 2 funding rounds.
Nalu Bio's investors include Intrinsic Capital Partners, Axial VC, Bonaventure Equity, Brown Angel Group, Flybridge Capital Partners, Golden Seeds, L37, Portfolia, Sacramento Angels, XFactor Ventures.
Nalu Bio has raised $14.0M across 2 funding rounds. Most recently, it raised $12.0M Series A in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 28, 2023 | $12M Series A | Intrinsic Capital Partners | Axial VC, Bonaventure Equity, Brown Angel Group, Flybridge Capital Partners, Golden Seeds, L37, Portfolia, Sacramento Angels | Announced |
| Jan 1, 2021 | $2M Seed | — | Sacramento Angels, XFactor Ventures | Announced |